DrugPatentWatch Database Preview
Details for Patent: 8,796,276
Which drugs does patent 8,796,276 protect, and when does it expire?
This patent has twenty-nine patent family members in eighteen countries.
Summary for Patent: 8,796,276
Title: | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Abstract: | Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. ##STR00001## |
Inventor(s): | Remenar; Julius F. (Framingham, MA), Blumberg; Laura Cook (Lincoln, MA), Zeidan; Tarek A. (Watertown, MA) |
Assignee: | Alkermes Pharma Ireland Limited (Dublin, IE) |
Application Number: | 13/607,066 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,796,276
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-001 | Oct 5, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | TREATMENT OF SCHIZOPHRENIA | ➤ Sign Up | ||||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-002 | Oct 5, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | TREATMENT OF SCHIZOPHRENIA | ➤ Sign Up | ||||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-003 | Oct 5, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | TREATMENT OF SCHIZOPHRENIA | ➤ Sign Up | ||||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-004 | Jun 5, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | TREATMENT OF SCHIZOPHRENIA | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,796,276
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,102,618 | Prodrugs of NH-acidic compounds | ➤ Sign Up |
8,431,576 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ➤ Sign Up |
8,686,009 | Prodrugs of NH-acidic compounds | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,796,276
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 077239 | ➤ Sign Up | |||
Australia | 2010266018 | ➤ Sign Up | |||
Australia | 2010266040 | ➤ Sign Up | |||
Canada | 2766033 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |